Therapeutics

Tools

Back to the Top
Search By Attributes

Search Results

Name Synonyms FDA Status Company Target Type Therapy Type Approved
For
AADvac1 Axon peptide 108 conjugated to KLH Alzheimer's Disease (Phase 2), Progressive Nonfluent Aphasia (Phase 1) Axon Neuroscience SE Tau Immunotherapy (active)
ACI-35 VAC20121,
JNJ-64042056
Alzheimer's Disease (Phase 2/3) AC Immune SA, Janssen Tau Immunotherapy (active)